S&P 500   5,128.84 (+0.64%)
DOW   39,059.22 (+0.16%)
QQQ   444.97 (+1.36%)
AAPL   178.68 (-1.15%)
MSFT   414.53 (+0.22%)
META   502.42 (+2.51%)
GOOGL   138.17 (-0.21%)
AMZN   178.06 (+0.74%)
TSLA   203.39 (+0.75%)
NVDA   818.04 (+3.40%)
NIO   5.83 (+1.39%)
AMD   200.89 (+4.34%)
BABA   74.79 (+1.03%)
T   16.97 (+0.24%)
F   12.43 (-0.08%)
MU   95.56 (+5.46%)
CGC   3.27 (-0.61%)
GE   159.09 (+1.40%)
DIS   111.90 (+0.29%)
AMC   4.41 (+2.08%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.77 (+1.20%)
S&P 500   5,128.84 (+0.64%)
DOW   39,059.22 (+0.16%)
QQQ   444.97 (+1.36%)
AAPL   178.68 (-1.15%)
MSFT   414.53 (+0.22%)
META   502.42 (+2.51%)
GOOGL   138.17 (-0.21%)
AMZN   178.06 (+0.74%)
TSLA   203.39 (+0.75%)
NVDA   818.04 (+3.40%)
NIO   5.83 (+1.39%)
AMD   200.89 (+4.34%)
BABA   74.79 (+1.03%)
T   16.97 (+0.24%)
F   12.43 (-0.08%)
MU   95.56 (+5.46%)
CGC   3.27 (-0.61%)
GE   159.09 (+1.40%)
DIS   111.90 (+0.29%)
AMC   4.41 (+2.08%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.77 (+1.20%)
S&P 500   5,128.84 (+0.64%)
DOW   39,059.22 (+0.16%)
QQQ   444.97 (+1.36%)
AAPL   178.68 (-1.15%)
MSFT   414.53 (+0.22%)
META   502.42 (+2.51%)
GOOGL   138.17 (-0.21%)
AMZN   178.06 (+0.74%)
TSLA   203.39 (+0.75%)
NVDA   818.04 (+3.40%)
NIO   5.83 (+1.39%)
AMD   200.89 (+4.34%)
BABA   74.79 (+1.03%)
T   16.97 (+0.24%)
F   12.43 (-0.08%)
MU   95.56 (+5.46%)
CGC   3.27 (-0.61%)
GE   159.09 (+1.40%)
DIS   111.90 (+0.29%)
AMC   4.41 (+2.08%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.77 (+1.20%)
S&P 500   5,128.84 (+0.64%)
DOW   39,059.22 (+0.16%)
QQQ   444.97 (+1.36%)
AAPL   178.68 (-1.15%)
MSFT   414.53 (+0.22%)
META   502.42 (+2.51%)
GOOGL   138.17 (-0.21%)
AMZN   178.06 (+0.74%)
TSLA   203.39 (+0.75%)
NVDA   818.04 (+3.40%)
NIO   5.83 (+1.39%)
AMD   200.89 (+4.34%)
BABA   74.79 (+1.03%)
T   16.97 (+0.24%)
F   12.43 (-0.08%)
MU   95.56 (+5.46%)
CGC   3.27 (-0.61%)
GE   159.09 (+1.40%)
DIS   111.90 (+0.29%)
AMC   4.41 (+2.08%)
PFE   26.57 (+0.04%)
PYPL   60.64 (+0.50%)
XOM   105.77 (+1.20%)
NASDAQ:SRGA

Surgalign (SRGA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.18
$1.22
52-Week Range
N/A
Volume
8.72 million shs
Average Volume
1.44 million shs
Market Capitalization
$1.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50

SRGA stock logo

About Surgalign Stock (NASDAQ:SRGA)

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. It offers products for thoracolumbar procedures, including Streamline TL spinal fixation system, a system for degenerative and complex spine procedures; and Streamline MIS spinal fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; and SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops augmented reality and artificial intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois. On June 19, 2023, Surgalign Holdings, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.


SRGA Stock News Headlines

Surgalign Holdings Inc.
Surgalign Holdings Inc (SRGAQ)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
RT20.BE - SURGALIGN HLDGS NEW -,001
Why Is Surgalign Holdings (SRGA) Stock Up 10% Today?
Short Volatility Alert: Surgalign Holdings
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Why Is Surgalign (SRGA) Stock Down 55% Today?
See More Headlines
Receive SRGA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surgalign and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Current Symbol
NASDAQ:SRGA
Employees
217
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.50
High Stock Price Target
$3.50
Low Stock Price Target
$3.50
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-54,600,000.00
Pretax Margin
-66.00%

Debt

Sales & Book Value

Annual Sales
$81.98 million
Book Value
($3.81) per share

Miscellaneous

Free Float
8,964,000
Market Cap
$1.69 million
Optionable
Optionable
Beta
1.55
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives















SRGA Stock Analysis - Frequently Asked Questions

Should I buy or sell Surgalign stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Surgalign in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SRGA shares.
View SRGA analyst ratings
or view top-rated stocks.

What is Surgalign's stock price target for 2024?

1 analysts have issued 12 month target prices for Surgalign's shares. Their SRGA share price targets range from $3.50 to $3.50. On average, they predict the company's share price to reach $3.50 in the next year.
View analysts price targets for SRGA
or view top-rated stocks among Wall Street analysts.

How were Surgalign's earnings last quarter?

Surgalign Holdings, Inc. (NASDAQ:SRGA) released its earnings results on Tuesday, November, 9th. The company reported ($3.60) EPS for the quarter, missing the consensus estimate of ($2.70) by $0.90. The firm earned $20.55 million during the quarter, compared to analyst estimates of $22.55 million. Surgalign had a negative net margin of 64.63% and a negative trailing twelve-month return on equity of 983.11%. During the same period in the previous year, the business earned ($3.30) EPS.

When did Surgalign's stock split?

Surgalign shares reverse split on the morning of Tuesday, May 17th 2022. The 1-30 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

This page (NASDAQ:SRGA) was last updated on 3/1/2024 by MarketBeat.com Staff